Peginterferon and TIL Therapy for Metastatic Melanoma

Exclusion Criteria

• •Other Malignancies, unless followed for ≥ 5 years with no sign of disease, except squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.
• •Cerebral metastasis. Patients with previously treated CNS metastases can participate if CNS metastases are surgically removed or treated with stereotactic radiosurgery and stable ≥ 28 days after treatment measured by MRI. Patients with asymptomatic, stable and untreated CNS metastasis can in be included according to investigators and sponsors decision.
• •Patients with ocular melanoma
• •Severe allergies, history of anaphylaxis or known allergies to the administered drugs.
• •Serious medical or psychiatric comorbidity
• •Creatinine clearance \< 70 ml/min
• •Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis
• •Severe and active autoimmune disease
• •Pregnant and nursing women
• •Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate
• •Concomitant treatment with other experimental drugs
• •Patients with uncontrolled hypercalcemia
• •Less than four weeks since prior systemic antineoplastic treatment at the time of treatment.
• •\-